XML 50 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has three reportable segments: Generics, Specialty, and AvKARE.
Generics
Generics develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals across a broad range of therapeutic categories. Generics’ retail and institutional portfolio contains approximately 250 product families, many of which represent difficult-to-manufacture products or products that have a high barrier-to-entry, such as oncologics, anti-infectives and supportive care products for healthcare providers.
Specialty
Specialty delivers proprietary medicines to the U.S. market. The Company offers a growing portfolio in core therapeutic categories including central nervous system disorders, endocrinology, parasitic infections and other therapeutic areas. The Company's specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Specialty also has a number of product candidates that are in varying stages of development.
AvKARE
AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, as well as medical and surgical products. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.
Chief Operating Decision Makers
The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision makers.
The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Year Ended December 31, 2021
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other		Total
Company
Net revenue$1,366,338 $378,319 $349,012 $— $2,093,669 
Cost of goods sold825,568 193,562 282,874 — 1,302,004 
Cost of goods sold impairment charges22,692 — — — 22,692 
Gross profit518,078 184,757 66,138 — 768,973 
Selling, general and administrative64,500 84,481 57,918 158,605 365,504 
Research and development158,365 43,482 — — 201,847 
In-process research and development impairment charges710 — — — 710 
Intellectual property legal development expenses7,562 154 — — 7,716 
Acquisition, transaction-related and integration expenses— 16 1,422 6,617 8,055 
Charges related to legal matters, net— — — 25,000 25,000 
Restructuring and other charges80 — — 1,777 1,857 
Change in fair value of contingent consideration — 200 — — 200 
Property losses and associated expenses, net5,368 — — — 5,368 
Operating income (loss)$281,493 $56,424 $6,798 $(191,999)$152,716 
Year Ended December 31, 2020
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other		Total
Company
Net revenue$1,343,210 $355,567 $293,746 $— $1,992,523 
Cost of goods sold894,422 192,910 242,219 — 1,329,551 
Cost of goods sold impairment charges34,579 — — — 34,579 
Gross profit414,209 162,657 51,527 — 628,393 
Selling, general and administrative56,134 75,917 58,544 136,132 326,727 
Research and development150,068 29,862 — — 179,930 
In-process research and development impairment charges2,680 — — — 2,680 
Intellectual property legal development expenses10,647 8 — — 10,655 
Acquisition, transaction-related and integration expenses328 85 641 7,934 8,988 
Charges related to legal matters, net5,610 250 — — 5,860 
Restructuring and other (credit) charges(614)— — 3,012 2,398 
Operating income (loss)$189,356 $56,535 $(7,658)$(147,078)$91,155 
Year Ended December 31, 2019
Generics (2)
Specialty (2)
Corporate
and Other		Total
Company
Net revenue$1,308,843 $317,530 $— $1,626,373 
Cost of goods sold984,782 162,432 — 1,147,214 
Cost of goods sold impairment charges119,145 7,017 — 126,162 
Gross profit204,916 148,081 — 352,997 
Selling, general and administrative68,883 79,665 141,050 289,598 
Research and development172,196 15,853 — 188,049 
In-process research and development impairment charges46,619 — — 46,619 
Intellectual property legal development expenses13,193 1,045 — 14,238 
Acquisition, transaction-related and integration expenses4,633 8,346 3,409 16,388 
Charges related to legal matters, net12,442 — — 12,442 
Restructuring and other (credit) charges20,101 391 13,853 34,345 
Operating (loss) income$(133,151)$42,781 $(158,312)$(248,682)
(1)Operating results for the sale of Amneal products by AvKARE were included in Generics effective with the closing of the Rondo Acquisitions on January 31, 2020.
(2)During the three months ended September 30, 2019, operating results for Oxymorphone were reclassified from Generics to Specialty, where it is sold as a non-promoted product.  Prior period results have not been restated to reflect the reclassification.